Case Report: Fruquintinib-induced hyperbilirubinemia: a rare cause of dialyzer filter discoloration in a patient undergoing long-term dialysis.

Frontiers in nephrology Pub Date : 2025-07-24 eCollection Date: 2025-01-01 DOI:10.3389/fneph.2025.1586520
Mercedes Galloway, Alaa S Awad, Charles W Heilig
{"title":"Case Report: Fruquintinib-induced hyperbilirubinemia: a rare cause of dialyzer filter discoloration in a patient undergoing long-term dialysis.","authors":"Mercedes Galloway, Alaa S Awad, Charles W Heilig","doi":"10.3389/fneph.2025.1586520","DOIUrl":null,"url":null,"abstract":"<p><p>We report a case of a 55-year-old male patient with a medical history of cardiorenal syndrome and rectosigmoid colon adenocarcinoma, who started dialysis five years prior to presenting with unusual yellow discoloration of his dialyzer filter during his regular dialysis session. Following a regimen of standard chemotherapy, the patient was initiated on fruquintinib, 5 mg daily for 21 days, as an alternative treatment due to the intolerability of previous agents and failure of malignancy to respond. Shortly after starting fruquintinib, the patient developed hyperbilirubinemia and experienced significant yellow discoloration of the dialysis filter-a phenomenon not previously documented in association with this medication. The absence of dialyzer discoloration during five years of dialysis highlights the temporal relationship between the introduction of fruquintinib and the onset of filter discoloration. [removed some sentence] This case highlights the need for heightened awareness of potential adverse effects of fruquintinib, potentially detectable in patients undergoing dialysis, and aims to contribute to the growing body of literature on the medication's safety profile.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1586520"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328136/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fneph.2025.1586520","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We report a case of a 55-year-old male patient with a medical history of cardiorenal syndrome and rectosigmoid colon adenocarcinoma, who started dialysis five years prior to presenting with unusual yellow discoloration of his dialyzer filter during his regular dialysis session. Following a regimen of standard chemotherapy, the patient was initiated on fruquintinib, 5 mg daily for 21 days, as an alternative treatment due to the intolerability of previous agents and failure of malignancy to respond. Shortly after starting fruquintinib, the patient developed hyperbilirubinemia and experienced significant yellow discoloration of the dialysis filter-a phenomenon not previously documented in association with this medication. The absence of dialyzer discoloration during five years of dialysis highlights the temporal relationship between the introduction of fruquintinib and the onset of filter discoloration. [removed some sentence] This case highlights the need for heightened awareness of potential adverse effects of fruquintinib, potentially detectable in patients undergoing dialysis, and aims to contribute to the growing body of literature on the medication's safety profile.

Abstract Image

Abstract Image

病例报告:氟喹替尼诱导的高胆红素血症:一个罕见的原因透析过滤器变色的病人接受长期透析。
我们报告一例55岁男性患者,有心肾综合征和直肠乙状结肠腺癌的病史,他在透析前5年开始透析,在他的常规透析期间,他的透析器过滤器出现不寻常的黄色变色。在标准化疗方案之后,患者开始使用fruquininib,每天5mg,连续21天,作为先前药物的不耐受和恶性肿瘤的失败反应的替代治疗。在开始服用fruquininib后不久,患者出现高胆红素血症,并经历了明显的透析滤过膜黄色变色——这一现象以前没有与该药相关的文献记录。在透析的五年中没有透析器变色突出了引入fruquininib和过滤器变色发病之间的时间关系。本病例强调了对fruquininib潜在不良反应的高度认识的必要性,在接受透析的患者中可能检测到,并旨在为越来越多的关于药物安全性的文献做出贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信